Physician profile
Darshan Arora
NPI 1316934383
$9,962.89
in general payments reported to CMS, 2019-2025
34 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $817 · 2021: $1,000 · 2022: $1,983 · 2023: $1,882 · 2024: $2,041 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,088 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,088.14 |
| Education | $234.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,349.87 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Mallinckrodt Hospital Products INC. | $1,074.28 | 2020-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $876.39 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $825.10 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $688.61 | 2021-2025 | Krystexxa, Tavneos, Parsabiv |
| Glaxosmithkline, LLC. | $578.02 | 2020-2025 | Benlysta, Jesduvroq, Shingrix |
| Vifor Pharma, INC. | $563.38 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $369.94 | 2021-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $330.76 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $318.44 | 2020-2025 | |
| Fresenius USA Marketing, INC. | $275.94 | 2019-2024 | Velphoro |
| Alexion Pharmaceuticals, INC. | $248.47 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $247.18 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $240.14 | 2022-2024 | Lupkynis |
| Novo Nordisk INC | $231.80 | 2019-2025 | Rivfloza, Ozempic |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshan Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.